HomeCompareCDBT vs MRK

CDBT vs MRK: Dividend Comparison 2026

CDBT yields 2000.00% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CDBT wins by $9939315158.47M in total portfolio value
10 years
CDBT
CDBT
● Live price
2000.00%
Share price
$0.10
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$9939315158.53M
Annual income
$9,049,252,674,478,578.00
Full CDBT calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — CDBT vs MRK

📍 CDBT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCDBTMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CDBT + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CDBT pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CDBT
Annual income on $10K today (after 15% tax)
$170,000.00/yr
After 10yr DRIP, annual income (after tax)
$7,691,864,773,306,791.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, CDBT beats the other by $7,691,864,773,298,463.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CDBT + MRK for your $10,000?

CDBT: 50%MRK: 50%
100% MRK50/50100% CDBT
Portfolio after 10yr
$4969657579.29M
Annual income
$4,524,626,337,244,188.00/yr
Blended yield
91.05%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

CDBT
No analyst data
Altman Z
-9.4
Piotroski
2/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CDBT buys
0
MRK buys
0
No recent congressional trades found for CDBT or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCDBTMRK
Forward yield2000.00%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$9939315158.53M$56.8K
Annual income after 10y$9,049,252,674,478,578.00$9,798.13
Total dividends collected$9876141646.27M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CDBT vs MRK ($10,000, DRIP)

YearCDBT PortfolioCDBT Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$210,700$200,000.00$11,206$366.19+$199.5KCDBT
2$4,163,767$3,938,317.76$12,650$502.35+$4.15MCDBT
3$77,191,133$72,735,902.82$14,407$694.19+$77.18MCDBT
4$1,342,813,676$1,260,219,163.76$16,585$967.82+$1342.80MCDBT
5$21,925,333,121$20,488,522,486.99$19,342$1,363.89+$21925.31MCDBT
6$336,109,296,351$312,649,189,912.21$22,913$1,947.19+$336109.27MCDBT
7$4,838,913,266,619$4,479,276,319,522.88$27,662$2,823.89+$4838913.24MCDBT
8$65,446,276,951,058$60,268,639,755,775.59$34,159$4,173.35+$65446276.92MCDBT
9$831,834,097,245,644$761,806,580,908,011.90$43,337$6,308.80+$831834097.20MCDBT
10$9,939,315,158,531,418$9,049,252,674,478,578.00$56,776$9,798.13+$9939315158.47MCDBT

CDBT vs MRK: Complete Analysis 2026

CDBTStock

China Dasheng Biotechnology Company, together with its subsidiaries, engages in the production, marketing, and distribution of bacteria based products used as additives for livestock feed and crop cultivation in the People's Republic of China. It provides artificial microorganisms (AM) and high-efficiency microorganism (HM) based biological bacterium blends; and biological preservatives. The company offers AM/HM bacteria based additives for crops, including Bulgaria lactobacillus, beer microzyme, and dark red spirilla used to increase the beneficial microorganism colonies in soil; inhibit the reproduction of harmful fungi and putrefactive bacteria; and to improve nutrient absorption and reduce crop and livestock diseases. It also provides AM/HM bacteria based additives for livestock feed, which softens the livestock feed and restrain the growth and reproduction of pathogenic bacteria, as well as supplies beneficial nutriments, including organic acid, vitamins, enzyme, antibiotics, mycelium protein, and other growth-enhancing substances that balance the nutrients in the feed. In addition, the company offers FGW bacterial based preservatives that preserve animal specimens for scientific research; and preserve the freshness for agricultural produce. Further, it provides bacteria based fertilizer for application on plants, such as vegetable and fruit leaves. Additionally, China Dasheng Biotechnology Company engages in residential and commercial real estate investment. The company was formerly known as Max Nutrition, Inc. and changed its name to China Dasheng Biotechnology Company in March 2008. China Dasheng Biotechnology Company is based in Lanzhou, China.

Full CDBT Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this CDBT vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CDBT vs SCHDCDBT vs JEPICDBT vs OCDBT vs KOCDBT vs MAINCDBT vs JNJCDBT vs ABBVCDBT vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.